A prototype miniaturized Iotal Chemical Analysis~ystem (lITAS) has been developed and applied to on-line monitoring of glucose and lactate in the core blood of anaesthetized dogs. The system consists of a highly efficient microdialysis sampling interface sited in a small-scale extracorporeal shunt circuit CMiniShunt'), a silicon machined microflow manifold and integrated biosensor array for glucose and lactate detection with associated computer software for analytical process control. During in-vivo testing the device allowed real-time on-screen monitoring of glucose and lactate with system response times of less than 5 min, made possible by the small dead volume of the microflow system. On-line glucose and lactate measurements were made in the basal state as well as during intravenous infusion of glucose or lactate. The prototype lITAS is currently suitable for trend monitoring but refinements are necessary before application of the system for determination of individual lactate values.
SUMMARY. A prototype miniaturized Iotal Chemical Analysis~ystem (lITAS) has been developed and applied to on-line monitoring of glucose and lactate in the core blood of anaesthetized dogs. The system consists of a highly efficient microdialysis sampling interface sited in a small-scale extracorporeal shunt circuit CMiniShunt'), a silicon machined microflow manifold and integrated biosensor array for glucose and lactate detection with associated computer software for analytical process control. During in-vivo testing the device allowed real-time on-screen monitoring of glucose and lactate with system response times of less than 5 min, made possible by the small dead volume of the microflow system. On-line glucose and lactate measurements were made in the basal state as well as during intravenous infusion of glucose or lactate. The prototype lITAS is currently suitable for trend monitoring but refinements are necessary before application of the system for determination of individual lactate values.
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The concept of a miniaturized Total chemical A nalysis System (lIT AS) encompassing automatic generation, transport and (where necessary) pre-treatment of samples coupled with online detection of analytes-transforming chemical information into electronic informationwas first proposed by Manz.' The design, fabrication and testing of a prototype lITAS suitable for biomedical applications is the subject of this report.
Patients admitted to an intensive care unit (ICU) or undergoing major operations require close monitoring of vital functions (arterial, central venous, and pulmonary capillary wedge blood pressures, core temperature, oxygen saturation, and urinary output). This is currently done by invasive techniques, i.e. catheter placement in vessels and body cavities. First-generation intra-Correspondence: Dr R Freaney, Metabolism Laboratory, St Vincent's Hospital, Elm Park, Dublin 4, Ireland. arterial probes for on-line continuous measurement of blood gas parameters (p02, PC0 2, pH, O 2 saturation and other derived values) have recently become available. Monitoring of systemic blood concentrations of other biochemical analytes, however, is currently still dependent on intermittent phlebotomy and discrete analysis. The extracorporeal microdialysis system described below was developed to satisfy the perceived requirements of high-efficiency on-line sampling of core blood to reflect systemic analyte concentrations in critically ill patients. The system as described in the report is a prototype which measures only two analytes but has the potential to be adapted for multi-analyte sensor arrays.
GLUCOSE AND LACTATE MONITORING
Enzyme membrane technology utilizing glucose oxidase for the amperometric detection of glucose is at an advanced stage? The Diabetes Freaney et at.
Control and Complications Trial Research
Group! reported significant reductions in microvascular complications of diabetes through tighter glycaemic control. However, this was accompanied by an increased incidence of hypoglycaemic episodes which emphasized the need for a continuous monitoring system.
Plasma lactate concentrations exceeding IOmmol/L are associated with 100% mortality." Current models for establishing probability of mortality (e.g. the APACHE II score and the Mortality Probability Index II) require collection of data over a 24 h interval for prediction of clinical outcome. Patient prognosis may be improved with earlier intervention which could be made possible by real-time lactate monitoring. Regional increases in plasma lactate have also been observed in response to arterial occlusion" as plasma lactate is a sensitive indicator of tissue hypoxia. Metabolic acidosis and lactic acidaemia may occur simultaneously, but the lack of relationship between lactate and hydrogen ion concentration is accepted" and lactic acidaemia may occur in the absence of pH or HCO] derangements, emphasizing the importance of lactate measurements.
/ITAS: DESIGN AND INSTRUMENTAnON
The instrumental design elements required to realize the concept of a /ITAS include an automatic sampling interface (a shunt microdialysis arrangement), a microflow manifold conveying either cali brant solution or sample to the sensor by means of a silicon wafer stack with micromachined grooves, a miniaturized integrated biosensor chip with multiple working electrodes. Computer software for overall process control and signal display was also developed. A schematic of the system elements in on-line detection mode is shown in Fig. I 
SAMPLING SYSTEM
Because of the heterogeneous nature of blood and tissue fluids a sample pre-treatment step producing a clean, protein-free sample may prolong the life of the sensor. Microdialysis'"? can provide a biocompatible sampling interface between patient and sensor and was therefore chosen as the sampling method. It allows determination of low-molecular weight endogenous compounds which diffuse passively from body fluids down a concentration gradient ... ;:: across a semi-permeable membrane into a continuously pumped perfusate solution. The resultant dialysate can be collected for serial discrete analysis or directed through a microflow system to an on-line sensor or sensor array. Microdialysis sampling probes are available in concentric, needle-type configuration (e.g. those commercially produced by CMA/Microdialysis, Stockholm, Sweden) or in linear configuration as used in these studies. Probes may be sited in subcutaneous interstitium10.11, organs such as brain!', liver" or muscle!", or intravascularly'>, the selected site depending on clinical requirements and feasibility.
In the setting of an acute severe illness, highefficiency sampling of true systemic analyte concentrations with a short system response time would be indicated and could be provided by sampling core plasma (i.e. arterial or central venous blood) using large probes and/or slow perfusion flow rates. In the setting of a chronic low-grade illness, less invasive approaches would be preferred, and easily accessible subcutaneous
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interstitium might be the site of choice. However, subcutaneous probe placement (usually in anterior abdominal adipose tissue) samples a very localized analyte pool which has been disturbed by the insertion of the probe, may not accurately reflect systemic concentrations'" and cannot be independently sampled for comparison by any other method. Needle-type probes are difficult to insert, and withdraw safely from all vascular sites and tend to operate at low efficiencies unless perfused extremely slowly.!" For these reasons, the sampling approach taken in this study consisted of the creation of a pumped low-volume, low-flow extracorporeal shunt circuit (the MiniShunt) serving to convey central venous blood to an externally placed, large linear microdialysis fibre. In clinical usage this would have the added practical advantages of utilizing pre-existing vascular access, and allowing visual inspection and probe exchange if necessary. Blood flow rate was set at 3'OmL/min and countercurrent micro dialysis perfusate flow from a precision syringe pump was set at 3·0 ilL/min. The principle of glucose and lactate measurement employed here is their oxidation by glucose oxidase (GOD) and lactate oxidase (LOD) enzyme electrodes, resulting in the production of hydrogen peroxide which is then oxidized to oxygen, hydrogen ions and current flow. The amperomctric signal generated at each working Conventional analytical flow manifolds serving to deliver alternative streams of cali brant or sample to the sensing cell are based on tubing having inner diameters ranging from O· 3 to I mm. These systems can have overall volumes in the low microlitre range, appropriate for microdialysis-based sampling. However, there are a few practical disadvantages associated with them. Tubing-based manifolds are constructed using various types of connecting pieces which require frequent maintenance, and which can prove to be a significant source of unwanted dead volume in the system. Since high microdialysis efficiency is achieved at very low microlitres per minute and even nanolitres per minute flow rates, avoidance of dead volume becomes an important issue in system design. An alternative route to achieving microflow systems is offered by silicon micromachining. This approach was applied in the current study. Standard double sided, single mask photolithographic etching techniques were employed to produce flow channel grooves on planar silicon substrates. A number of chips (22 mm square, diameter 380/lm; examples given in Fig. 3 a) micromachined in this way were stacked on top of one another to construct a three-dimensional module known as a microflow stack ( Fig. 3 b) . IX Elements can be designed to incorporate simple flow channels or complex entities such as Tjunctions, mixing chambers and reaction coils with virtually no dead volume between them. Channels are 600/lm wide across the top and
PVC tubing

MICROFLOW SYSTEM
The microdialysis probes ( Fig. 2) were fabricated from aminocellulose (AC) hollow fibre (Hemophan'", Akzo Nobel Membrana, Wuppertal, Germany, molecular weight cut-off 6000 Da) into which silica microcapillary segments were inserted to a distance of I em at both ends (resulting in lficm fibre length with an internal surface area of 100mm? being available for sampling). The fibre was then threaded through the lumen of polyvinyl chloride (PVC) tubing by means of a 20 cm long nephrostomy needle. The inlet and outlet were reinforced with l S-gauge polyethylene tubing, using a methacrylate glue. The probe fibre was then sequentially flushed with 70% isopropanol, 5% glycerol, and sterile water, and the PVC tubing lumen was flushed with ultrafiltered water under pressure. The completed AC-lOO probes were sterilized before insertion using ethylene oxide gas.
(a)
INTEGRAnON OF MICROFLOW SYSTEM AND BIOSENSORS FIGURE 4. Schematic of the thin-film multilayer enzyme membrane (a) (the semi-permeable membrane has been omitted from this diagram) (h). Cross-section of biosensor chip.
(b)
Glass cover
Individual enzyme electrodes
Au counter electrode basic precursor without the enzymes) IS applied on top of the enzyme membranes as well as over the Ag/AgCI reference electrode. Topmost, a catalase membrane of 5 J1m thickness is applied to prevent cross-talking and to reduce flow sensitivity. A cross-section of the completed biosensor membrane is shown in Fig. 4 a.
The assembled biosensor chip ( Fig. 4 b) consists of the sensing device and a gold counter electrode which forms the bottom of the measuring cell, deposited on a piece of printed circuit board (PCB) which has been specially adapted to fit under the assembled microflow stack inside their common holder and to allow electrical signal conduction by means of an ordinary single-sided PCB edge connector ( Fig.  5 ). Because the microflow channels are easily blocked by contamination, the preparation of stack and sensor for experiments involved firstly cleaning each silicon wafer in distilled water by sonication, followed by methanol, trichloroethylene, methanol and finally water again. The wafers were then dried under nitrogen and the stack unit assembled, with the sensor chip at the bottom, in a dust-free clean room environment. 
••••••1Anode
A microflow biosensor cell for integration into the microflow stack was produced at the Technical University of Vienna. Inter-centre cooperation between partners in Berlin and Vienna was required to select optimal sensor membrane specifications. Thin film working electrode arrays were manufactured using thin-layer, photo-patternable multi-enzyme membranes." 21 A photo-crosslink able hydrogel membrane precursor solution, typically consisting of 47% hydroxyethyl methacrylate (HEMA, Merck) as reactive monomer, 47% p(HEMA) (Polyscience) as polymeric binder, 5% tetraethylene glycol dimethacrylate (Aldrich) as crossliner, and 1% w.w-dimethoxy-w-phenylacetophene (Aldrich) as photo initiator, dissolved in a water/ethylene glycol mixture, is used to immobilize glucose oxidase and lactate oxidase, respectively, by means of physical entrapment. Fifty nanolitres of each enzyme membrane precursor are deposited on the corresponding working electrodes and subsequently crosslinked under ultraviolet flood light for I min using a mask aligner under Argon flushing. Multiple sets of working electrodes were manufactured from platinum surfaces evaporated onto an alkali silicate glass slide of 300 J1m thickness by an electron gun under high vacuum conditions, and modified by a multistep process employing plasma-enhanced chemical vapour deposition (PECVD) of a silicon nitride insulation layer and plasma etching with 02/CF4. The formed electrode pattern comprises five 0·5 mm square electrodes per device and 45 devices per production wafer. The platinum working electrode surfaces are subsequently roughened by platinization (increasing their surface area lOa-fold) and finally covered with an electropolymerized semipermeable membrane made by potentiodynamic deposition of 1,3-diaminobenzene before application of the enzyme containing layer. After development, the enzyme membranes show a dry thickness of 6 J1m. In order to realize the desired linear measuring range, an 8 J1m thick diffusion limiting membrane (made using the electrode is thus directly proportional to the analyte concentration within the linear range of the device:
. Microflow stack and integrated biosensor in common holder with electrical connector to potentiostat, The assembled microfiow system with integrated biosensor cell has a combined internal dead volume of approximately 8 pL and showed a total system response time (lag time) of 4-5 min and sensor response time for both analytes was < lOs.
Sample inlet
Waste outlet
PCB edge connector
Holder Screw-down teflon cover Silicon wafer microflow stack over a four week period ranged from 2·25 to 3·20 nA/mmol for glucose and from 3040 to 4·08 nA/mmol for lactate.
COMPUTER SOFTWARE
Analytical process control and data acquisition was exerted by means of a virtual instrument entitled Microdialysis Control System constructed using the LabView 3·0 graphical programming system for instrumentation (National Instruments, Texas, USA). 22 The computer software controls microdialysis perfusate/ cali brant pump speed or refill, valve assembly settings for injection of calibrant or microdialysate through the sensor, and data acquisition for calculation of glucose and lactate concentration based on two-point calibration. The software was adapted for use with a notebook personal computer (Latitude 450 Me, Dell Corp, Austin TX, USA) and offers direct current/concentration interconversion. Optimization of high speed communications required a separate data acquisition module (DAQ PAD 1200, National Instruments). Recalibrations of the sensors were not programmed but may be carried out at userdefined intervals. In this study calibration was performed at the start of each experiment and at approximately 2 h intervals thereafter.
SENSOR CALIBRATION
After installation of the biosensor chip in the microflow stack and initial flow checks to exclude flow blockages or leaks, the biosensor electrode were conditioned by perfusion with the microdialysis perfusate buffer (a modified Dulbecco's physiological salt solution, containing 0·2g/L KH 2P04 , 1·15g/L K 2HP04 , 2·1 giL NaHC0 3 , 0·2g(L KCl, 7·54g(L NaCI and 60 mg/L Enoxaparin-a low molecular weight heparinoid; overall pH = 8·37 and osmolality = 303 mosmol(L) until a stable baseline below 1·0 nA/mmol was attained, which constitutes background current. Aqueous calibration solutions containing glucose and lactate at concentrations of 1·0 and 004mrnol/L (low cali brant) and 10 and 4mmol/L (high calibrant), respectively, were then injected consecutively until a stable signal was attained for each. Slope and intercept of the resulting two-point calibration curves for glucose and lactate were determined and used for subsequent current/calibration interconversion. Sensitivity of the biosensors Ann Clin Biochem 1997: 34
PERFORMANCE EVALUATION OF SYSTEM COMPONENTS
Before application of the total system, the components were characterized and tested. Microdialysis efficiency is conventionally expressed as percent relative recovery of analyte:
Factors capable of affecting microdialysis performance (perfusate and matrix flow rate, membrane material, size, and sterilization, and temperature) were investigated and will be the subject of a separate report. Results obtained using discrete sample analysis with a stat analyzer had shown that in-vitro % RR for glucose and lactate with fibre sizes in excess of 70 rnrrr' at a perfusate flow rate of 3 IlL(min is better than 95%. The in-vivo studies were therefore performed under these optimized conditions.
ON-LINE IN-VIVO GLUCOSE AND LACTATE MONITORING WITH THE INTEGRATED SYSTEM: EXPERIMENTAL PROTOCOL
Following multi-centre collaborative research resulting in the design and fabrication of a prototype J.lTAS, in-vivo studies in anaesthetized dogs were performed. Studies employing on-line continuous analysis of core blood glucose and lactate were conducted under a licence from the Department of Health and with the approval of the Hospital Ethics and Medical Research Committee. Eight experiments were performed in five greyhound dogs (average weight 26.5 kg) following a protocol established previously.P Animals were premedicated, following which anaesthesia was induced intravenously and maintained with a halothane/oxygen mixture breathed spontaneously through an endotracheal tube. Analgesia and antibiotic cover were provided. Normal saline was given as required for hydration, and heparin [at a dosage of 100 iU/kg by in vivo bolus followed by 25 iU /kg hourly] was administered to maintain shunt patency. Animals were monitored peri-operatively by electrocardiogram and invasive arterial blood pressure monitoring. Access to central vessels was established by transfemoral cutdown and insertion of single-lumen catheters into central vessels, or jugular cut-down with insertion of a triple-lumen catheter into the right atrium of the heart. The catheters were capped with subcutaneously implanted bungs. The sterile MiniShunt circuit containing an AC-100 microdialysis sampling probe was connected and a peristaltic roller pump (lnfusomat Debio, B Braun Melsungen, Germany) activated. Microdialysis perfusate was injected continuously through a valve assembly into the dialysis fibre at 3 J.lL/min in a countercurrent direction to the blood flow by a precision syringe pump (CMA/ 100, CMA, Stockholm, Sweden). The microdialysate generated in the probe flowed through the microflow stack into the integrated biosensor. Microdialysate samples were collected at IS min intervals from the microflow stack waste outlet into glass capillaries (Clinitubes's, Radiometer Copenhagen, Denmark) for discrete analysis alongside the timed plasma samples on a YSI 2300 Stat Plus glucose and lactate analyser (YSI, Ohio, USA) whose coefficients of variation for glucose and lactate had been previously confirmed to be within the manufacturer's specifications of < I·5% (linear range 0-
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50 mmol/L for glucose and 0-30 mrnol/L for lactate). On-line measurements were made in the basal state as well as during infusion of lactate (0,5 mrnol/kg bolus followed by 2·5 mmol/kg/h infusion) and glucose (2,5 mmol/kg bolus followed by 2·5 mmol/kg/h infusion) designed to simulate pathophysiological metabolic derangements.
In each experiment, three sets of glucose and lactate measurements were made: fB/ M D Microdialysate from the MiniShunt sampling probe was analysed on-line by the integrated biosensor which carried an array of four working electrodes (one glucose, two lactate, and one blank) 2 YSf/MD Microdialysate emerging from the outlet of the integrated system was collected in 15min aliquots for discrete analysis by YSI instrument 3 YSf/PL Core plasma (obtained from blood samples taken near the micro dialysis probe at the midpoint of each 15 min sampling period and separated immediately using a refrigerated centrifuge) was collected for discrete analysis by YSI instrument.
The glucose and lactate samples for method comparison were not generated in an exactly similar manner. The on-line IB/MD yielded a large number of readings (n = 75) over a 15 min interval and the value used for comparison was the integrated mean value. The microdialysate which had accumulated during the 15 min period was used to give a single discrete measurement by YSI analyser. The plasma glucose and lactate values were midpoint values for each IS min period and would be dependent on steady-state assumption; and where glucose or lactate was infused, on the distribution of infused analyte. For this reason, results obtained during periods of rapidly changing analyte concentrations were excluded from analysis. Agreement between methods (and samples) was analysed using the Altman Bland method in which difference between results is plotted against the mean of the two methods. The scatter of glucose values about the mean increased with increasing concentration and results were therefore log transformed. On reverse log transformation, the agreement between methods is expressed as the mean ratio (bias) of one set of values compared to the other and the 95% limits of agreement [(LOA) ( Table  I) ]. For lactate, results were not log transformed the YSI/PL value. Microdialysate lactate concentrations measured by IB lie between 0-43 mrnol/L below and 0-49 mrnol/L above those measured by YSI. These limits of agreement for lactate are unacceptably wide, reflecting the small sample size in addition to method and sampling variation. The mean basal lactate 
RESULTS
Midpoint plasma glucose values compared to microdialysate glucose concentration measured by YSI or IB did not show significant bias (Table  I) . For glucose, the 95% LOA for microdialysate analysed by IB (IB/MD) and plasma analysed by YSI (YSI/PL) show that 95% of IB/MD results lie between 0·73 and 1·34 times the plasma glucose concentration. The YSI/MD results have a 95% LOA of 0·81 to 1·22 times the YSI/PL value. Microdialysate glucose concentrations measured by IB lie between 0·71 to 1·38 times those measured by YSI.
Lactate on-line IB/MD measurements showed significant negative bias compared to plasma or microdialysate lactate concentrations measured using YSI ( Table 2 ). The bias showed that IB/MD values were 0·049mmol/L lower and 0·026 mrnol/L higher than those of plasma YSI and microdialysate YSI, respectively. The LOA for microdialysate analysed by IB and plasma by YSI show that 95% of IB/MD results are between 0'56mmol/L lower and 0-46mmol/L higher than the PL/YSI lactate concentration. The YSI/MD results have a 95% LOA ranging from 0'38mmol/L below to 0·28mmol/L above and agreement between methods (and samples) is summarized as the mean difference (bias) and the 95% LOA ( Table 2 ).
Ann C/in Biochem 1997: J4
On-line biochemical sensing of glucose started as early as 1963 when Kadish constructed a closedloop bedside artificial pancreas/" capable of continuous blood glucose detection. An ambulatory device was described in 1969. 25 More recent embodiments of this principle are the Biostator'" 26 and the Ulm Zuckeruhr'v (Glucosensor Unitec Ulm)27 which was subsequently adapted for lactate measurements." All of these devices are associated with some unavoidable blood loss as the sample is not returned to the circulation.
Direct tissue implantation in subcutaneous sites of mono-analyte sensors,29.30 and microdialysis sampling coupled to external on-line sensors for glucose.l'<" lactate'" or both," have been explored. Flow-through glucose sensors have been implanted in vascular grafts. 36.37 An alternative approach involving extracorporeal haemodialysis sampling on a reduced scale has also been described.P tracings of microdialysate glucose and lactate and also show symbols representing glucose and lactate results obtained by discrete analysis of plasma and microdialysate using the YSI analyser. Spike artifacts in the tracing were associated with mechanical movement of the microflow/biosensor assembly during exchange of capillaries for sample collection. Figure 7 a shows a relatively stable on-line signal for glucose. The lactate signal in Figure 7 b is less stable but does reflect the increments in plasma lactate, and microdialysate lactate measured by lB and YSI. Figure 8 shows some discordance between lB/MD glucose and YSI/PL glucose at hyperglycaemic concentrations. This discordance may be related to the failure of midpoint plasma glucose measurements to adequately reflect the mean glucose concentration over a IS min period when intravenous administration of glucose causes a rapid 20 rnmol/L increase in plasma glucose concentration.
While Altman Bland analysis was the method used to examine the agreement between methods and samples, the relationship between YSI measurements of PL and MD and MD analyte concentrations measured by the prototype IB was expressed by the Pearson correlation coefficient. Correlation of YSI/PL analyte concentrations with lB/MD and YSI/MD measurements yielded r values of 0·98 and 0·99 (P<O·OOOI), respectively, for glucose, and 0·96 and 0·98 (P<O·OOl), respectively, for lactate. concentrations were very low ( < 0·6 mmol/L) in the animals studied. Figure 6 shows Altman Bland plots of microdialysate glucose measured by integrated biosensor and plasma glucose measured by YSI, with and without log transformation. All glucose data was subsequently log transformed.
DISCUSSION
Figures 7 a-b and 8 show on-line lB signal
The direct implantation of sensors for monitoring glucose and/or other analytes in tissue has to date proved disappointing because of calibration difficulties and signal decay with time.I? Poor biocompatibility of the implant." loss of biosensor enzyme into the surrounding tissue 41 ,42 and the generation of a postulated interferent substance Q43 have been advanced to explain these findings. Intravascular sensor implantation has been complicated by coagulation problems.v'-"
Recent publications have proposed wearable glucose sensor systems based on direct tissue implantation using novel coatings which are claimed to substantially improve sensor performance and Iifetime.rv" Others46-48 have performed true in-vivo two-point calibration by means of a glucose tolerance test (GTT). However, these developments were aimed at a monoanalyte sensing system for ambulatory diabetic patients employing subcutaneous sampling, and the need for repeated GTTs would be cumbersome in clinical practice. It is as yet unproven whether muiti-analyte sensors with improved biocompatibility and suitably small dimensions for direct implantation can be realized. A microflow system similar to ours but responding only to glucose and achieving much lower microdialysis efficiency has recently been proposed.t?
The clinical and technical requirements for J1.TAS system for on-line biochemical monitoring include robustness and reliability with respect to stability of signal, accurate reflection of systemic analyte concentrations, convenient and biocompatible interfacing with the patient, readily replaceable components, and low cost (achievable through the use of cheap materials and simple machining processes).
Results obtained in the relatively short-term studies (up to 4h duration) presented above demonstrate that a miniaturized on-line analytical system for real-time glucose and lactate monitoring in core blood has been produced. The system is capable of following systemic analyte concentrations not only at pathophysiologically elevated concentrations but also under basal conditions. Lactate signal was more variable than glucose signal and showed unacceptable lack of agreement between results. This may at least partly reflect small sample size (n = 28) and the very low basal lactate concentrations normally encountered in greyhounds. Some on-line sensor signal tracings and discrete measurement results are shown in Figs 7 and 8, and indicate that it is currently useful for trend monitoring.
Ann Clin Biochem 1997: 34
Ideally, method comparison can be performed using split fractions of the same plasma sample and different assay methods. In these studies, samples were of different matrix composition, i.e. plasma and microdialysate. Methods of sample generation were different and the use of midpoint blood samples assumed steady-state conditions which may not have prevailed especially over the 15 min MD collection periods following in-vitro glucose and lactate infusion. Any or all of these factors may have contributed to the limited agreement between on-line microdialysate analyte monitoring by integrated biosensor and plasma concentration results measured by the YSI analyser.
The difference observed between results of microdialysate measurements made by YSI analyser on samples after passage through the integrated biosensor chamber, and plasma YSI analyte measurements is in part due to the imprecision of both measurements. In addition, some analyte is consumed by the reaction during passage through the biosensor and this may be more significant for lactate at the low concentration encountered. It may also result from the fact that the samples did not represent exactly the same point in time, the plasma represented the midpoint value of the 15 min collection period for the microdialysate sample. Diminution in solute transfer across the dialysis membrane due to depletion of analyte which may occur during tissue or subcutaneous microdialysis is unlikely to have contributed to the discordance as a steady flow of core blood was being continuously dialysed at a flow rate of 3 ml.rrnin.
The J1.TAS we designed, fabricated and tested is to our knowledge the first on-line in-vivo intravascular sensing system for simultaneous lactate and glucose monitoring. It is, however, a prototype system, and further developments are required before application in a clinical setting. Novel features of the system comprise the highly efficient intravascular microdialysis sampling interface, the microflow fluid manifold stack with integrated biosensor array on a PCB-based chip, and the virtual control instrument, and the rapid response to system response using intravascular sampling. Aspects requiring further development are elimination or reduction of the systemic heparin requirement to prevent blood clotting in the MiniShunt, improvements to lactate sensor stability to improve accuracy and precision, device failure alarm and quality assurance (QA) issues. These could be respectively addressed by reducing the thrombo-genicity of the PVC tubing surface through either covalently bonded heparin or chemical modification, by minor modifications to the lactate sensor system including its electrical connections, and by making a QA material available on the syringe pump for use following sensor calibration. Further miniaturization of the system is being explored and will become possible mainly through reduction in size of the pump elements and of the separate data acquisition and control element which can be replaced by a PCMCIA card in the expansion slot of the notebook computer. Future developments in printed circuit board manufacturing technology which will allow the creation of a fluid manifold adjacent to the microflow biosensor cell are the subject of ongoing research. The development of a wider range of biosensors for incorporation into the array is also being pursued actively. Longer duration invivo studies will be required to determine the effective in-situ lifetime of the biosensors. The use of microdialysis to prepare a protein-free sample for analysis is in our view an important step in improving sensor performance and lifetime. In addition, sampling of this type avoids depleting the patient of blood cells and fluid. The advantage of the extracorporeal sampling shunt are that it can be connected readily with a pre-existing multi-lumen central venous catheter in the target population of ICU patients to allow core blood sampling. In addition, the external location of the probe allows calibration and QA issues to be more readily addressed, and component exchange is easy. The invasiveness of this approach limits its application in ambulatory patients.
